Recent Research Analysts’ Ratings Changes for ICON Public (ICLR)

Several analysts have recently updated their ratings and price targets for ICON Public (NASDAQ: ICLR):

• 10/28/2024 – ICON Public had its price target lowered by analysts at Truist Financial Co. from $363.00 to $295.00. They now have a “buy” rating on the stock.
• 10/25/2024 – ICON Public had its price target lowered by analysts at Barclays PLC from $330.00 to $275.00. They now have an “overweight” rating on the stock.
• 10/25/2024 – ICON Public had its price target lowered by analysts at JPMorgan Chase & Co. from $375.00 to $280.00. They now have an “overweight” rating on the stock.
• 10/25/2024 – ICON Public had its price target lowered by analysts at Leerink Partners from $376.00 to $270.00. They now have an “outperform” rating on the stock.
• 10/25/2024 – ICON Public had its price target lowered by analysts at TD Cowen from $369.00 to $285.00. They now have a “buy” rating on the stock.
• 10/25/2024 – ICON Public had its price target lowered by analysts at The Goldman Sachs Group, Inc. from $370.00 to $280.00. They now have a “buy” rating on the stock.
• 10/24/2024 – ICON Public was downgraded by analysts at Robert W. Baird from an “outperform” rating to a “neutral” rating. They now have a $340.00 price target on the stock.
• 10/24/2024 – ICON Public was downgraded by analysts at Baird R W from a “strong-buy” rating to a “hold” rating.
• 10/15/2024 – ICON Public had its price target lowered by analysts at Barclays PLC from $350.00 to $330.00. They now have an “overweight” rating on the stock.
• 10/14/2024 – ICON Public is now covered by analysts at Redburn Atlantic. They set a “neutral” rating and a $311.00 price target on the stock.
• 10/14/2024 – ICON Public had its price target lowered by analysts at Truist Financial Co. from $383.00 to $363.00. They now have a “buy” rating on the stock.
• 10/8/2024 – ICON Public had its price target lowered by analysts at Evercore ISI from $360.00 to $350.00. They now have an “outperform” rating on the stock.
• 9/20/2024 – ICON Public had its price target lowered by analysts at Robert W. Baird from $368.00 to $340.00. They now have an “outperform” rating on the stock.
• 9/19/2024 – ICON Public was downgraded by analysts at StockNews.com from a “buy” rating to a “hold” rating.
• 9/18/2024 – ICON Public was upgraded by analysts at Leerink Partnrs to a “strong-buy” rating.
• 9/18/2024 – ICON Public is now covered by analysts at Leerink Partners. They set an “outperform” rating and a $379.00 price target on the stock.
• 9/11/2024 – ICON Public had its “outperform” rating reaffirmed by analysts at Robert W. Baird. They now have a $368.00 price target on the stock.
• 9/11/2024 – ICON Public was upgraded by analysts at StockNews.com from a “hold” rating to a “buy” rating.
• 9/11/2024 – ICON Public had its “buy” rating reaffirmed by analysts at Truist Financial Co.. They now have a $383.00 price target on the stock.

ICON Public Stock Down 1.2 %

NASDAQ:ICLR traded down $2.71 during trading hours on Wednesday, reaching $223.71. The company’s stock had a trading volume of 1,465,242 shares, compared to its average volume of 662,838. The company has a debt-to-equity ratio of 0.35, a current ratio of 1.34 and a quick ratio of 1.34. ICON Public Limited has a one year low of $217.67 and a one year high of $347.72. The business’s 50-day moving average is $284.01 and its 200-day moving average is $306.63. The company has a market cap of $18.46 billion, a price-to-earnings ratio of 24.94, a price-to-earnings-growth ratio of 1.63 and a beta of 1.25.

ICON Public (NASDAQ:ICLR) last posted its quarterly earnings data on Wednesday, October 23rd. The medical research company reported $3.35 earnings per share for the quarter, missing the consensus estimate of $3.72 by ($0.37). The firm had revenue of $2.03 billion for the quarter, compared to analyst estimates of $2.13 billion. ICON Public had a return on equity of 11.91% and a net margin of 9.00%. The business’s quarterly revenue was down 1.2% on a year-over-year basis. During the same period in the previous year, the business posted $3.10 EPS. Equities research analysts predict that ICON Public Limited will post 13.43 EPS for the current year.

Hedge Funds Weigh In On ICON Public

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Ashton Thomas Private Wealth LLC acquired a new stake in shares of ICON Public during the second quarter worth $54,000. ORG Partners LLC acquired a new stake in ICON Public in the 2nd quarter valued at $59,000. Whittier Trust Co. of Nevada Inc. increased its stake in ICON Public by 410.8% in the 1st quarter. Whittier Trust Co. of Nevada Inc. now owns 189 shares of the medical research company’s stock valued at $63,000 after buying an additional 152 shares during the last quarter. GAMMA Investing LLC increased its stake in ICON Public by 50.0% in the 2nd quarter. GAMMA Investing LLC now owns 261 shares of the medical research company’s stock valued at $82,000 after buying an additional 87 shares during the last quarter. Finally, EverSource Wealth Advisors LLC increased its stake in ICON Public by 17.4% in the 1st quarter. EverSource Wealth Advisors LLC now owns 283 shares of the medical research company’s stock valued at $95,000 after buying an additional 42 shares during the last quarter. 95.61% of the stock is owned by institutional investors.

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.